Among the monoclonal antibodies utilized for treating lung cancer are anti-CTLA-4 antibody ipilimumab, anti-PD-1 antibodies pembrolizumab and nivolumab, and anti-PD-L1 antibodies atezolizumab, durvalumab, and avelumab [62]. This evidence concerns the gene CD274 and lung cancer.